Bladder Cancer Classification and Treatment Using Atezolizumab

The USPTO published patent application US20260092117A1 for methods of classifying and treating bladder cancer using atezolizumab. The application discloses diagnostic methods (potentially involving biomarker analysis, CPC classification C12Q 1/6886) and therapeutic methods involving administration of the PD-1 axis binding antagonist atezolizumab to patients with bladder cancer, including locally advanced or metastatic urothelial cancer. The patent application names three inventors and covers compositions, kits, and articles of manufacture for these methods.

Pharmaceutical companies developing or commercializing immunotherapies, healthcare providers treating bladder cancer patients, and clinical laboratories performing cancer diagnostics should review the published claims to assess potential intellectual property implications. Patent applications do not create compliance obligations or deadlines; they represent pending intellectual property claims that may affect future product development or treatment protocols if granted.